Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy

Journal of Digestive Diseases

Volumn 15, Issue 4, 2014, Pages 174-179

  Sherman, Michael ^a   Tsynman, Donald N ^b   Kim, Albert ^b   Arora, Jyoti ^b   Pietras, Timothy ^b   Messing, Susan ^b   St Hilaire, Lydia ^b   Yoon, Sonia ^b   Decross, Arthur ^b   Shah, Ashok ^b   Saubermann, Lawrence ^b  

^a San Antonio Uniformed Services Health Education Consortium   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Inflammatory bowel disease; Inflammatory bowel disease questionnaire; Quality of life; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COLITIS; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; EUROQOL 5; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VISUAL ANALOG SCALE; YOUNG ADULT; ZUNG SELF RATING DEPRESSION SCALE;

INFLAMMATORY BOWEL DISEASE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; QUALITY OF LIFE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GASTROINTESTINAL AGENTS; HEALTH STATUS INDICATORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84896274307     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12125     Document Type: Article

References (38)

1. Casellas F, Arenas JI, Baudet JS etal. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 488-496.
2. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1603-1609.
3. Casellas F, López-Vivancos J, Vergara M, Malagelada J. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999; 17: 208-218.
4. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35-42.
5. Irvine EJ. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol 1997; 92: 18S-24S.
6. Turnbull GK, Vallis TM. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol 1995; 90: 1450-1454.
7. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379-1386.
8. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005; 39: 390-395.
9. Reinisch W, Sandborn WJ, Bala M etal. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1135-1140.
10. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006; 12: 697-707.
11. Riss S, Schwameis K, Mittlböck M etal. Sexual function and quality of life after surgical treatment for anal fistulas in Crohn's disease. Tech Coloproctol 2013; 17: 89-94.
12. Irvine EJ, Feagan B, Rochon J etal. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-296.
13. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009; 104: 1976-1983.
14. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101-109.
15. Loftus EV, Feagan BG, Colombel JF etal. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-3141.
16. Rutgeerts P, Schreiber S, Feagan B etal.; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008; 23: 289-296.
17. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
18. Sandborn WJ, Feagan BG, Stoinov S etal. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
19. Schreiber S, Khaliq-Kareemi M, Lawrance IC etal.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250.
20. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007; 102: 2737-2746.
21. Feagan BG, Reinisch W, Rutgeerts P etal. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
22. Ghosh S, Nwokolo C. Maintenance therapy with natalizumab improves quality of life in patients with Crohn's disease. Gut 2005; 54: A23.
23. Schreiber S, Rutgeerts P, Fedorak RN etal.; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818.
24. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003; 98: 2232-2238.
25. Hanauer SB, Feagan BG, Lichtenstein GR etal.; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
26. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8: 237-243.
27. van Balkom BP, Schoon EJ, Stockbrügger RW etal. Effects of anti-tumour necrosis factor-α therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1101-1107.
28. Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007; 13: 1395-1400.
29. Guyatt G, Mitchell A, Irvine EJ etal. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810.
30. König HH, Ulshöfer A, Gregor M etal. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 1205-1215.
31. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-343.
32. Biggs JT, Wylie LT, Ziegler VE. Validity of the Zung self-rating depression scale. Br J Psychiatry 1978; 132: 381-385.
33. Pallis AG, Mouzas IA. Instruments for quality of life assessment in patients with inflammatory bowel disease. Dig Liver Dis 2000; 32: 682-688.
34. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444-454.
35. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28: S23-27.
36. Irvine EJ. Quality of life - measurement in inflammatory bowel disease. Scand J Gastroenterol Suppl 1993; 199: 36-39.
37. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis 2013; 7: 467-473.
38. Jones J. The effects of non-response on statistical inference. J Health Soc Policy 1996; 8: 49-62.